Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Receivables: 2010-2024

Historic Receivables for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $38.4 million.

  • Ligand Pharmaceuticals' Receivables rose 67.73% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.7 million, marking a year-over-year increase of 31.97%. This contributed to the annual value of $38.4 million for FY2024, which is 16.58% up from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Receivables is $38.4 million, which was up 16.58% from $32.9 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Receivables peaked at $85.5 million during FY2021, and registered a low of $30.4 million during FY2022.
  • In the last 3 years, Ligand Pharmaceuticals' Receivables had a median value of $32.9 million in 2023 and averaged $33.9 million.
  • In the last 5 years, Ligand Pharmaceuticals' Receivables surged by 87.08% in 2020 and then tumbled by 64.40% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Receivables (Yearly) stood at $56.8 million in 2020, then surged by 50.32% to $85.5 million in 2021, then plummeted by 64.40% to $30.4 million in 2022, then climbed by 8.19% to $32.9 million in 2023, then climbed by 16.58% to $38.4 million in 2024.